Company / Total Assets
Immix Biopharma, Inc. Total Assets History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$22.9M
FY2025
5-year range
$19.9M / $22.9M
FY2023-FY2025
Trend
+0.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $20M to $23M over the past 2 years.
Based on SEC 10-K filings.
$23M in FY2025.
Improved from $20M to $23M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, total assets increased 0.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.9M | +0.0% |
| FY2024 | $22.9M | +15.2% |
| FY2023 | $19.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026